Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806121 | 0.94 | NR1I2 (0.43) | NR1I2CYP3A4CYP2C19SCN9APRKCA | |
| SCHEMBL1807198 | 0.93 | NR1I2 (0.42) | NR1I2CYP3A4CYP2C19SCN9APRKCA | |
| SCHEMBL752222 | 0.89 | NR1I2 (0.54) | NR1I2CYP3A4CYP2C19SCN9APRKCA | |
| SCHEMBL13936875 | 0.88 | NR1I2 (0.46) | NR1I2CYP3A4CYP2C19SCN9AUSP14 | |
| SCHEMBL13936882 | 0.87 | NR1I2 (0.47) | NR1I2SCN9AUSP14PRKCAMMP12 | |
| SCHEMBL1804942 | 0.86 | NR1I2 (0.44) | NR1I2CYP3A4SCN9APRKCAMMP12 | |
| SCHEMBL51345 | 0.85 | NR1I2 (0.43) | NR1I2CYP3A4CYP2C19SCN9AKCNH2 | |
| SCHEMBL14876364 | 0.83 | NR1I2 (0.44) | NR1I2CYP3A4SCN9APRKCAMMP12 | |
| SCHEMBL13936876 | 0.83 | NR1I2 (0.62) | NR1I2SCN9AUSP14 | |
| SCHEMBL1734178 | 0.82 | NR1I2 (0.58) | NR1I2CYP3A4CYP2C19SCN9APRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-8921355-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN R & D IRELAND (IE) | 2014-12-30 | — | — | US | disclosed |
| US-8921355-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN R & D IRELAND (IE) | 2014-12-30 | — | — | US | disclosed |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | JANSSEN R&D IRELAND (IL) | 2014-04-17 | — | — | US | disclosed |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | JANSSEN R&D IRELAND (IL) | 2014-04-17 | — | — | US | disclosed |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-05 | — | — | US | disclosed |
| WO-2010003658-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, CCNI | NR1I2 234/4885CYP3A4 91/4885CYP2C19 303/4885 |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | IDO1, HCCS, CCNI | NR1I2 234/4885CYP3A4 91/4885CYP2C19 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.